ArticleBMC endocrine disorders2026
The relationship between stigma and illness acceptance in type 2 diabetes and determining factors: a cross-sectional study.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with type2 diabetes frequently face prejudices that result in feelings of stigma, creating an adverse feedback loop that both degrades their quality of life and complicates the management of their illness. The aim of this study is to determine the relationship between stigma and illness acceptance in type 2 diabetes mellitus and the factors that determine it.
methodsThe research was conducted as a cross-sectional descriptive study and between January and June 2025 at the endocrinology clinic of an university hospital. The study included 96 patients. Data were collected using a personal information form, the Type 2 Diabetes Stigma Assessment Scale (DSAS-2), and Acceptance of Illness Scale (AIS). The data were analysed using IBM SPSS 25.0 software. A STROBE checklist was the reporting guide for this study.
resultsParticipants’ DSAS-2 and AIS total mean scores were 46.56 ± 14.44 and 22.93 ± 6.25, respectively. A positive correlation has been determined between DSAS-2 and AIS scores. (R = 0.560, p < 0.001). Participants who had diabetes for 6–11 years, received combination therapy (insulin and oral antidiabetic agents), were hospitalised due to DM in the past year, and required assistance with care had higher DSAS-2 and AIS scores compared to others (p < 0.05). Multiple regression analysis showed that the type of diabetes treatment was a significant determinant of DSAS-2 and AIS scores.
conclusionPatients receiving combination therapy demonstrated significantly higher stigma scores and greater illness acceptance compared to other treatments. The correlation between stigma and acceptance of illness is positive. Authors suggest that acceptance of illness should not always be perceived as having a positive effect. It is strongly recommended to incorporate stigma screening into the management plan of patients requiring both insulin and oral antidiabetic drugs. A comprehensive evaluation of patients with diabetes must account for both stigma and illness acceptance concurrently. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.